ANI Pharmaceuticals Inc. (NASDAQ:ANIP) shares are down early Friday following the company’s strong fourth-quarter report.
ANI Pharmaceuticals reported adjusted earnings of $2.33 per share, up from $1.63 a year ago, beating the consensus of $2.00.
Total net revenues for the fourth quarter reached $247.1 million, marking a 29.6% increase compared to the same period last year. The sales surpassed the consensus estimate of $231.53 million.
The Rare Disease segment, which includes products like Cortrophin Gel, saw a remarkable 50.8% growth, contributing $131.3 million to the overall revenue.
In addition, ANI reported a net income of $27.5 million for the fourth quarter, translating to $1.18 per diluted share, a significant turnaround from a net loss of $10.7 million in the prior year.
Adjusted EBITDA for the fourth quarter of 2025 was $65.4 million, an increase of 30.6% from the fourth quarter of 2024.
Expects Over $1 Billion In 2026 Sales
“2025 was a year of significant growth for our Rare Disease and Generics businesses, which drove expansion to both our top-and bottom-line,” said Nikhil Lalwani, President and CEO of ANI.
Lalwani expects “significant multi-year growth” for Cortrophin Gel as the company expands into underpenetrated specialty indications and launches a dedicated organization for acute gouty arthritis flares.
Guidance
“With a proven track record, we expect to deliver more than $1 billion in revenue in 2026, with Rare Disease representing approximately 60% of total revenue,” Lalwani added.
For fiscal 2026, ANI expects sales between $1.055-$1.115 billion versus the consensus of $982.54 million.
The guidance includes Cortrophin Gel sales expectation of $540 million – $575 million, and ILUVIEN sales guidance of $78-$83 million.
ANI Pharmaceuticals sees fiscal 2026 adjusted earnings of $8.83-$9.34 per share compared to the consensus of $8.58, with adjusted EBITDA of $275 million – $290 million.
Technical Analysis
The stock is currently trading 5.2% above its 20-day simple moving average (SMA) and 8.1% below its 100-day SMA, indicating some short-term strength but potential resistance in the longer term. Over the past 12 months, shares have increased by 20%, and they are currently positioned closer to their 52-week highs than lows.
The RSI is at 50.00, which is considered neutral territory, indicating a balanced market sentiment. Meanwhile, MACD is at 0.15, below its signal line at 0.22, suggesting bearish pressure on the stock.
The combination of neutral RSI and bearish MACD indicates mixed momentum, reflecting uncertainty in the stock’s near-term direction.
- Key Resistance: $99.50
- Key Support: $54.10
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $95.50. Recent analyst moves include:
- Guggenheim: Buy (Raises Target to $124.00) (Jan. 16)
- Barclays: Initiated with Overweight (Target $100.00) (Dec. 9, 2025)
ANIP Price Action: ANI Pharmaceuticals shares were up 3.71% at $80.01 during premarket trading on Friday, according to Benzinga Pro data.
Image: Shutterstock
